Hypertrophic cardiomyopathy: State-of-the-art review, with focus on the management of outflow obstruction

Internal Medicine Journal

Volumn 33, Issue 11, 2003, Pages 521-529

  Kovacic, J C ^a   Muller, D W M ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Hypertrophic cardiomyopathy; Hypertrophic obstructive cardiomyopathy; Outflow obstruction; Percutaneous transluminal septal myocardial ablation

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE COURSE; DRUG EFFECT; DUAL CHAMBER ARTIFICIAL HEART PACEMAKER; ECHOCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; GENE MUTATION; GENETIC VARIABILITY; GENETICS; GENOTYPE PHENOTYPE CORRELATION; HEART ATRIUM FIBRILLATION; HEART OUTFLOW TRACT OBSTRUCTION; HEART SURGERY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IATROGENIC DISEASE; INTERVENTIONAL RADIOLOGY; MYOMECTOMY; PATHOLOGICAL ANATOMY; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL SEPTAL MYCOARDIAL ABLATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SUDDEN DEATH;

ALGORITHMS; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; DEATH, SUDDEN, CARDIAC; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HEMODYNAMIC PROCESSES; HUMANS; PROGNOSIS; RISK ASSESSMENT; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 0344304389     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00475.x     Document Type: Review

References (46)

1. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997; 350: 127-33.
2. Spinto P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-85.
3. Louie EK, Edwards LC III. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994; 36: 275-08.
4. Wynne J, Braunwald E. The cardiomyopathies and myocarditides. In: Braunwald, E, Zipes, DP, Libby, P, eds. Heart Disease: A Textbook of Cardiovascular Medicine, 6th edn. Philadelphia: W.B. Saunders; 2001; 1751-806.
5. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-20.
6. Maron BJ. Hypertrophic cardiomyopathy. Curr Probl Cardiol 1993; 18: 639-704.
7. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quiñones MA et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999; 99: 344-7.
8. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quiñones MA et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34: 1123-8.
9. McKenna WJ, Coccolo F, Elliott PM. Genes and disease expression in hypertrophic cardiomyopathy. Lancet 1998; 352: 1162-3.
10. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995; 92: 1680-92.
11. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002; 87: 169-76.
12. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 1596-01.
13. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420-4.
14. Maron BJ, Nichols PF, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by m-mode and two-dimensional echocardiography. Am J Cardiol 1984; 53: 1087-94.
15. Feigenbaum H. Echocardiography, 5th edn. Baltimore: Lippincott Williams, Wilkins; 1993.
16. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W et al. Mutations in the gene for cardiac myosin-binding protein c and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338: 1248-57.
17. Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG et al. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein c gene mutations. J Am Coll Cardiol 2001; 38: 315-21.
18. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein c gene. Circulation 1998; 97: 2230-6.
19. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982; 307: 997-9.
20. McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, Oakley CM et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984; 54: 802-10.
21. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-6.
22. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 1999; 99: 2927-33.
23. Knight CJ. Five years of percutaneous transluminal septal myocardial ablation. Heart 2000; 83: 255-6.
24. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994; 90: 2731-42.
25. Fananapazir L, Cannon RO III, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation 1992; 85: 2149-61.
26. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992; 339: 1318-23.
27. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997; 29: 435-41.
28. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34: 191-6.
29. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-4.
30. Kuhn HJ, Sigwart U. Induced septal infarction/nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 97: 709-10.
31. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001; 38: 1994-00.
32. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy, long term follow up of the first series of 25 patients. Heart 2000; 83: 326-31.
33. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-21.
34. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 2000; 21: 704-7.
35. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 1750-5.
36. Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH III, Nagueh SF. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 37: 208-14.
37. Faber L, Seggewiss H, Ziemssen P, Gleichmann U. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Cathet Cardiovasc Intervent 1999; 47: 462-6.
38. Gietzen FH, Leuner ChJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J 1999; 20: 1342-54.
39. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997; 95: 2075-81.
40. Fernandes VL, Nagueh SF, Lakkis NM, Franklin J, Roberts R, Spencer WH III. The long-term follow-up results of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor experience (1996-2001). J Am Coll Cardiol 2002; 39: 157A.
41. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-6.
42. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 2000; 355: 425-6.
43. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH III. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000; 36: 852-5.
44. Spirito P, Maron BJ. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 33: 1071-5.
45. Kim JJ, Lee CW, Park SW, Hong MK, Lim HY, Song JK et al. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1999; 83: 1220-3.
46. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103: 1492-6.